Freenome vs Ibex Medical Analytics
Ibex runs on slide images in pathology laboratories, and Freenome's test is a blood-based colorectal screen, so one buyer is a lab director and the other a screening clinician. Ibex Prostate Detect is FDA-cleared under 510(k) K241232, decision January 24, 2025, under the name Galen Second Read. Ibex sells to laboratories and health systems on enterprise contracts and describes its Breast, Breast HER2 and Gastric products as research use in the US.
Freenome's SimpleScreen CRC, approved as PMA P250029, screens for colorectal cancer from age 45. Per Freenome's July 2026 release, Abbott will exclusively commercialize it in the US from fall 2026, while Freenome develops it.
Urology Times, reporting on the Ibex FDA summary, cites 99.6% positive predictive value for heatmap accuracy and says pathologists without the AI missed 13% of the cancers it found.
Pathology · Reviewed November 2, 2026
Freenome
by Freenome · founded 2014
FDA-approved SimpleScreen CRC blood test for colorectal cancer screening in adults 45 and older at average risk.
Ibex Medical Analytics
by Ibex
AI pathology software for prostate, breast and gastric cancer. One US FDA 510(k) clearance, for prostate.
When to pick each one
Freenome
- PMA-approved colorectal blood test, ages 45 and older
- Abbott to commercialize from fall 2026, per release
Ibex Medical Analytics
- Prostate AI second reader, 510(k) K241232
- Vendor lists an open API to scanners, image management and LIS
- CE marked, plus UK and Brazil registration
Score
Each row shows points earned of points available under the published rubric.
Freenome
40of 100
Ibex Medical Analytics
33of 100
| Dimension | Freenome | Ibex Medical Analytics | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 0 / 21 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Freenome
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Ibex Medical Analytics
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Sold to laboratories and health systems on enterprise contracts. |
Evidence
Freenome
FDA decisions
P250029 (opens in new tab)PMA2026-07-24
SimpleScreen CRC
Ibex Medical Analytics
FDA decisions
K241232 (opens in new tab)510(k)2025-01-24
Galen Second Read (Ibex Prostate Detect)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Freenome | Ibex Medical Analytics |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2014 | n/a |
| HQ | US | IL |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.